163 results about "Systemic toxicity" patented technology

The invention discloses an RGD-click chemical crosslinking siRNA nano-carrier, a preparation method thereof and application of the nano-carrier in preparation of a medicine for treating secondary thyroidism, and belongs to the technical field of medicines.The nano-carrier is RGD-PEG-PLys (N), and the preparation method of the nano-carrier comprises the steps of synthesis of PLys (ss-DBCO), synthesis of RGD-PEG-PLys (N) and the like. According to the application, the nano-carrier is used for preparing siRNA composite nanoparticles; vascular endothelial targeting (RGD), dynamic stability (click crosslinking) and microenvironment responsiveness (disulfide bond) are organically combined for the first time to achieve mutual synergistic interaction, and the effect ceiling of an existing material is broken through; according to the siRNA composite nanoparticle, the silence effect of the PTH gene as long as 70 days can be achieved through single intravenous injection, the PTH inhibition rate is larger than 85%, the siRNA accumulation amount in parathyroid gland tissue is remarkably increased through RGD targeting (8.6 times that of a non-targeting group), the liver and kidney distribution amount is reduced by 60%, and the system toxicity is controllable.

The invention discloses a nano-enzyme microneedle system for remodeling a diabetes wound microenvironment to promote healing and a preparation method of the nano-enzyme microneedle system. The nano-enzyme microneedle system comprises nano-enzyme and a microneedle carrier, the nano-enzyme is prepared by a self-assembly method and is loaded in the microneedle carrier; the microneedle carrier is composed of a hydrogel matrix and is molded into a microneedle array through 3D printing; according to the system, the nano-enzyme can be delivered to the corium layer by penetrating the cuticle of the skin through the microneedle. The traditional Chinese medicine composition has the advantages that ROS (reactive oxygen species) is efficiently removed, oxidative stress injury induced by high glucose (HG) is relieved, immune cell polarization is regulated, inflammatory factor release is regulated and controlled, the chronic inflammation state of wound surfaces is relieved, cell proliferation and migration are promoted, neovascularization is accelerated, the healing speed of the diabetic wound surfaces is obviously increased, inflammation infiltration is reduced, granulation tissue formation and collagen deposition are obviously improved, and the effect of treating diabetes mellitus is achieved. And no systemic toxicity is observed. Through the synergistic effect of resisting oxidation, resisting inflammation and promoting angiogenesis, the pathological microenvironment of the diabetic wound is effectively improved.

The invention relates to an immune sensitization IRE treatment platform based on NK cell membrane coated manganese carbonate. A manganese carbonate composite nano material is formed by coating the surfaces of manganese carbonate nano particles with cell membranes. According to the invention, higher tumor specificity enrichment is realized, non-target tissue accumulation and systemic toxicity risks are reduced, collaborative integration of tumor targeted delivery, immune activation and IRE ablation is realized, and compared with single IRE, anti-tumor immune response is significantly enhanced.

The invention belongs to the technical field of medicines, and discloses preparation and application of a paclitaxel-loaded liposome nano targeting preparation. The paclitaxel-entrapped nano-particles are prepared by adopting a film dispersion method, and micromolecular hyaluronic acid is entrapped on the surfaces of the lipid nano-particles by utilizing the charge effect. The bionic nano-drug provided by the invention is helpful for solving the problems of poor solubility, low bioavailability, high toxicity and the like of the anticancer drug paclitaxel. The hyaluronic acid has affinity with a glycoprotein CD44 receptor on the surface of a tumor cell, so that the nanoparticles are targeted and concentrated at a tumor part, the anti-tumor effect is improved, and the systemic toxicity of paclitaxel is reduced. The preparation process is simple, the cost is low, the stability is good, the repeatability is high, and the preparation method also has a better development prospect in the aspect of clinical application transformation.

The invention relates to the technical field of biomedical engineering and drug delivery, and particularly discloses a novel targeted drug delivery system based on rose fruit extracellular vesicles, which comprises the following steps: preparing rose fruit source extracellular vesicles; preparing a medicine carrying vesicle; preparing targeted modified drug-loaded vesicles; according to the application disclosed by the invention, a stem related pathway is specifically down-regulated through the components of the rose fruits, and meanwhile, conventional tumor cells are killed by using adriamycin, so that a complementary treatment mechanism is formed, and the tumor recurrence risk is fundamentally reduced. The phenylboronic acid group of DSPE-PEG-PBA is used for specifically recognizing sialic acid over-expressed on the surface of a tumor cell, so that the enrichment of the medicine in tumor tissues is remarkably improved, and meanwhile, the distribution of normal tissues is reduced. By means of the natural biocompatibility and low immunogenicity of the RHNVs and in combination with the long circulation characteristic of a PEG chain, the delivery efficiency is guaranteed, the systemic toxicity is reduced to the maximum extent, and particularly the cardiotoxicity and myelosuppression of adriamycin are relieved.

The application discloses a kind of partition delivery environment response type hydrogel microneedle and its preparation method and application in oral squamous carcinoma treatment.The hydrogel microneedle includes backing layer and the needle tip layer being arranged on the surface of the backing layer, the needle tip layer includes multiple array distribution microneedle tip body, each the needle tip body is connected with the backing layer respectively;Wherein, the backing layer has enzyme response, and the needle tip layer has acidic pH response.The microneedle uses innovative "integration partition design", and two hydrogels with different functions are integrated in single microneedle array: backing layer responds oral flora imbalance microenvironment, needle tip layer responds tumor weak acidic microenvironment.The design can realize partition, accurate, intelligentized synergistic treatment to oral mucosa surface and deep tumor tissue, so as to overcome the technical bottleneck of traditional dosage form in space selectivity, single drug type, release behavior uncontrollable and great systemic toxicity etc.

The invention discloses a glucan-based MMAE conjugate as well as a preparation method and application thereof, and relates to the technical field of medicines. The conjugate takes glucan with good biocompatibility as a carrier, and is covalently connected with a cytotoxic drug MMAE through a VC peptide linker capable of being cut by cathepsin B. The conjugate has good serum stability, can specifically release drugs at a tumor site, and realizes efficient tumor uptake by virtue of the stealth effect of glucan and potential GLUT1 targeting. In-vitro and animal experiments show that the conjugate has a remarkable treatment effect on pancreatic cancer and is low in systemic toxicity.

The invention relates to the technical field of biological pharmacy, in particular to an application of N-[(3-chlorphenyl) methyl]-5-methyl-4-[(morpholine-4-yl) methyl]-1, 2-azole-3-formamide in preparation of an anti-melanoma drug and a preparation method of the N-[(3-chlorphenyl) methyl]-5-methyl-4-[(morpholine-4-yl) methyl]-1, 2-azole-3-formamide. According to the invention, specific pharmacophore and hydrophobic / hydrophilic modification are introduced in structure, so that the combination selectivity and stability of the compound and a target spot are improved; on the action mechanism, the compound can effectively interfere with a Bcl-3 signal channel. In-vivo experiments prove that the compound disclosed by the invention has a good tumor inhibition effect in an animal model, meanwhile, no obvious systemic toxicity is observed, and a relatively high therapeutic index is shown. In addition, the compound has good physicochemical properties and synthesis process feasibility, is convenient for industrial production, and is expected to become a novel candidate drug for clinical melanoma resistance.

The invention discloses in-situ drug-loaded synergistic treatment gel P-GFe-coated Gel as well as a preparation method and application thereof, and belongs to the field of biological medicines. By integrating the photo-thermal characteristics of mesoporous polydopamine (MPDA), the CDT efficiency of Fe, the TME regulation effect of glucose oxidase (GOx) and the in-situ delivery capacity of protein hydrogel, PTT / CDT synergistic treatment is achieved, and the problems that in existing tumor treatment, targeting is insufficient, the curative effect is limited by TME, and systemic toxicity is high are solved. The preparation technology is simple and mild, raw materials are easy to obtain, large-scale production can be achieved, and wide application prospects are achieved in clinical treatment of malignant tumors such as breast cancer.

A fusion antibody and its application. The fusion antibody includes: a) IL-15; b) IL-15Ra; and c) an antibody targeting a therapeutically relevant cell surface antigen. The antibody includes a heavy chain variable region (VH), a heavy chain constant region (CH1), a light chain variable region (VL), and a light chain constant region (CL). IL-15 / IL-15Ra is located between the C-terminus of the heavy chain variable region VH and the N-terminus of the heavy chain constant region CH1, and between the C-terminus of the light chain variable region VL and the N-terminus of the light chain constant region CL. This fusion antibody prolongs its half-life and, utilizing its targeting properties, specifically reaches its target site to exert its effect, conferring IL-15 with unique cell targeting properties. It exerts its receptor activation effect only in an environment containing high receptor concentrations of IL-2βγ, thus reducing the systemic toxicity of the IL-15 / IL-15Ra complex.

The application relates to the technical field of biological medicine, and discloses a targeted ferroptosis-inducing conjugate as well as a preparation method and application thereof. The structural formula of the conjugate is as follows: the conjugate contains a prostate cancer targeting peptide segment WHDGFK, and is connected with an iron death-inducing antibacterial peptide KRIVKWIIKLLR through a disulfide bond, so that the conjugate has tumor targeting and microenvironment response release functions, not only endows the antibacterial peptide KRIVKWIIKLLR with tumor selective delivery capacity, but also realizes specific release of the active peptide in target cells by reducing the disulfide bond by using high-concentration glutathione (GSH) in tumor cells, thereby synergistically enhancing the antitumor effect and reducing the systemic toxicity.

The invention belongs to the technical field of biological medicines, and particularly provides an ALO-coated F127-MOF nano-composite as well as a preparation method and application thereof. According to the ALO (at) F127-MOF nano compound, UiO-66-NH2 MOF with a pluronic F-127 coating is used as a nano carrier, and aloperine is loaded on the nano carrier. The nano compound is used for treating ALI, the solubility, stability and bioavailability of the traditional Chinese medicine aloperine are effectively improved, and the synergistic effect of sustained release of aloperine, ROS neutralization and effective targeting is achieved. The aerosolization-based delivery approach ensures better oxygenation, lower systemic toxicity, and better pulmonary deposition. The invention provides a new treatment method for noninvasive acute lung injury treatment.

The invention discloses a drug delivery system containing loaded adriamycin as well as a preparation method and application of the drug delivery system. The drug delivery system comprises poly (beta-amino ester) coupled with adriamycin, wherein the surface of the poly (beta-amino ester) is coated with dextran sulfate, and the poly (beta-amino ester) takes a fourth-generation lysine dendritic molecule Lys-G4 as a core. The drug delivery system has a pH-dependent drug release characteristic, has remarkable toxicity to C6 and U87MG glioma cells, has the capabilities of inducing apoptosis, inhibiting migration and targeting subcellular localization, and can effectively penetrate through a blood-brain barrier model and 3D tumor spheres. The delivery system is compounded with PLA-PEG-PLA thermosensitive hydrogel, and the thermosensitive hydrogel with a drug storage function is successfully constructed. Good tumor inhibition effect and biocompatibility are shown in nude mouse subcutaneous and in-situ glioma models. The invention not only provides a new strategy for overcoming the blood brain barrier, but also can effectively reduce the systemic toxicity, and opens up a new research thought and method for glioma treatment.

The invention discloses an application of an engineered mRNA (messenger Ribonucleic Acid) medicine for coding COL3A1 protein in resisting skin photoaging. According to the method, accurate rational design and optimization are carried out on the 5'untranslated region (UTR) of the hCOL3A1 mRNA, so that the translation efficiency and the protein yield of the hCOL3A1 mRNA are greatly improved, the expression level of the hCOL3A1 target protein far beyond the conventional sequence in vivo and in vitro is realized, and the type III collagen is efficiently and endogenously synthesized in skin cells. Experimental results show that the engineered mRNA can effectively reduce the skin oxidative stress level, inhibit cell aging and promote endogenous synthesis and deposition of corium layer collagen, so that the barrier function of photoaged skin is remarkably improved, the dermis thickness is increased, the tissue structure is repaired, and systemic toxicity or immune side effects are not observed. The invention provides a novel strategy with high efficiency and safety for resisting skin photoaging.

An ABT-263-loaded drug delivery system comprises a liposome and elemental gold, ABT-263 is loaded in the liposome, and the liposome is coated with the elemental gold to form a gold shell (Lipo-atABT263-atAu). Through verification, the senescent cell scavenger (ABT-263) and the golden shell liposome are integrated together to achieve the purposes of sensitizing radiation and continuously releasing drugs. In in-vitro experiments, the Lipo-ABT263-coated Au enhances cell apoptosis induced by radiation therapy, eliminates radiation-induced senescence tumor cells, and inhibits the tumor promoting effect of senescence-related secretion phenotypes. In an animal model, a drug delivery system remarkably inhibits tumor growth, skin fibrosis induced by radiotherapy is relieved through targeted aging fibroblasts, and systemic toxicity is not shown.

The invention provides a subdural hematoma targeted drug delivery system, a preparation method thereof and a pharmaceutical preparation, and belongs to the technical field of targeted drugs. The targeted drug delivery system is a drug-loaded liposome, and the drug-loaded liposome comprises a drug active substance and a liposome carrier loaded with the drug active substance; the liposome carrier is prepared from the following components: cholesterol, lecithin, DSPE-PEG (Distearoyl Phosphate Polyethylene-Polyethylene Glycol) and DSPE-PEG-CLTX. The targeted drug delivery system provided by the invention is spherical, small and uniform in particle size, negatively charged on the surface and good in serum stability, can deliver the drug to the subdural hematoma part in a targeted manner, reduces systemic toxicity of the drug, inhibits pyroptosis, relieves inflammatory response, promotes hematoma absorption and meningeal lymphatic vessel drainage, and has a good application prospect. And the purpose of accurate treatment is achieved.

The invention discloses a gene therapy nose drop for preventing and / or treating coronavirus as well as preparation and application of the gene therapy nose drop, and belongs to the technical field of biological medicines. The nose drop comprises a reagent A and a reagent B. The reagent A is a nano-gene therapy drug solution connecting a self-assembled composite nano-material carrier and a targeted nucleic acid cleavage system through a click reaction, and the cleavage system comprises endonuclease molecules and an hpDNA oligonucleotide probe set. The hpDNA probe can target a coronavirus N gene conserved sequence and a host cell CtslmRNA at the same time through stem-loop structural design, can cut virus RNA to inhibit replication of the virus RNA, and can block the activation process of virus spike protein; the reagent B is an inhalable preparation of an anti-inflammatory chemical drug, and the drug absorption efficiency is remarkably improved by regulating inflammatory reaction. The nose drop can efficiently prevent and treat coronavirus infection and respiratory tract complications caused by the coronavirus infection through a triple mechanism of'gene editing-host regulation-anti-inflammatory treatment 'in combination with the advantage of nasal local administration, and has the obvious characteristics of high bioavailability and low system toxicity.

The present application relates to the technical field of biological medicine, and particularly relates to application of fullerenol in preparation of tumor prevention or treatment drugs for inducing trained immunity. The present application finds that fullerenol can induce formation of trained immunity, activate immune reprogramming of bone marrow hematopoietic stem cells, produce long-term pro-inflammatory phenotype, form persistent immune memory, and further enhance functions of innate immune cells. It is verified by experiments that fullerenol can significantly inhibit tumor growth in an animal model without obvious systemic toxicity; epigenetic remodeling of bone marrow hematopoietic stem cells can be sustained for several weeks to several months, and has long-acting anti-recurrence potential. In addition, trained immunity induced by fullerenol can be used for immune regulation of various solid tumors, and fullerenol is simple in synthesis, can be produced on a large scale, has excellent biocompatibility and stability. Therefore, the present application has wide application prospect.

The application discloses a new use of androsta-4,6,8(9),13(14)-tetraen-3,11,16-trione, namely, application of the androsta-4,6,8(9),13(14)-tetraen-3,11,16-trione in preparation of a medicine for treating lymphoma. 50 The IC value of the androsta-4,6,8(9),13(14)-tetraen-3,11,16-trione in the SR cell line is detected by a CCK-8 method, and the cytotoxicity of the androsta-4,6,8(9),13(14)-tetraen-3,11,16-trione on human umbilical vein endothelial cells Huvce and human immortalized keratinocytes Hacat is detected, in the body, the androsta-4,6,8(9),13(14)-tetraen-3,11,16-trione significantly inhibits tumor growth and shows good biological safety and no systemic toxicity; TUNEL staining, gamma-H2AX staining and neutral comet experiment prove that the compound of the application inhibits the growth of SR by causing serious damage to DNA, the application not only adds the diversity of the biological activity of the androsta-4,6,8(9),13(14)-tetraen-3,11,16-trione, but also provides a new direction for developing a new medicine for treating lymphoma.

This invention belongs to the field of DNA hydrogel technology, specifically relating to a VEGF-responsive, on-demand release smart DNA hydrogel of glycyrrhizin, its preparation method, and its applications. This invention constructs a VEGF-responsive smart DNA hydrogel, efficiently encapsulating glycyrrhizin within a three-dimensional gel network, utilizing the high expression of VEGF in the tumor microenvironment to trigger on-demand drug release. This invention achieves precise on-demand release of glycyrrhizin, significantly improving drug utilization efficiency and reducing systemic toxicity. Simultaneously, the VEGF aptamer introduced into the system can specifically bind to and neutralize free VEGF, blocking angiogenesis, cutting off tumor nutrient supply, and further inhibiting tumor proliferation and progression, achieving a synergistic effect of intelligent drug delivery and anti-angiogenesis.

The invention belongs to the technical field of biological medicine, and relates to a releasable pegylated sirolimus compound and application thereof. The invention provides a releasable PEGylated sirolimus compound. The compound can be self-assembled to form micelles, prepared into nanoparticles and targeted to immune cells, regulates the release behavior of drugs, reduces the system toxicity and prolongs the biological half-life period. And moreover, the sirolimus-hydrophilic PEG conjugate has a proper hydrophobic sirolimus end and a hydrophilic PEG chain end, can effectively release drugs in immune cells, and is a good carrier for preparing nanoparticles. The invention provides a releasable PEGylated sirolimus compound, a nano-drug and a pharmaceutical composition prepared from the releasable PEGylated sirolimus compound, and application of the releasable PEGylated sirolimus compound in preparation of drugs for reducing immune response.

The application belongs to the technical field of biomaterial preparation, and particularly relates to a composite drug delivery system based on macrophage membranes and a preparation method and application thereof. The composite drug delivery system takes a lipid nanoparticle as a drug targeting delivery carrier, coats quercetin through an active phagocytosis mode, coats a macrophage membrane on the surface of the lipid nanoparticle, and constructs a quercetin lipid nanoparticle coated with a macrophage membrane (MCM@QU@LNP). The composite drug delivery system provided by the application can promote drug enrichment in RA lesions, improve local drug exposure, realize precise drug delivery in the RA part, has good biological safety, and reduces system toxicity.

This application relates to the field of pharmaceutical technology, and in particular to a topical ointment formulation and its preparation method. The formulation uses Sonicate as the active ingredient, combined with petrolatum, liquid paraffin, a solubilizing and penetration-enhancing system, and emulsifiers as excipients, to form an O / W type cream, an oil-based or water-soluble ointment. The preparation process employs a low-temperature dosing method at 40°C to ensure drug activity and inhibit crystallization. This application achieves high-concentration retention in local skin tissue through topical administration, significantly reducing radiation damage scores and pathological damage, while resulting in extremely low systemic plasma exposure, avoiding the systemic toxicity of oral administration, and providing a safe and efficient means for the clinical prevention and treatment of radiation-induced skin damage.

The invention discloses an anti-cervical cancer nano targeting tablet based on a traditional Chinese medicine compound and a preparation method thereof. The nano targeting tablet is prepared from the following raw materials in parts by weight: centipede, bungarus parvus, syngnathus, scorpio, nidus vespae, leech, ground beeltle, frankincense, myrrh, dandelion, rhizoma cyperi, radix bupleuri, fructus aurantii, cortex phellodendri, angelica sinensis, radix curcumae, poria cocos, bighead atractylodes rhizome, radix paeoniae alba, cortex albiziae, Chinese yam, oldenlandia diffusa and selfheal. According to the invention, active ingredients of the traditional Chinese medicinal materials are retained and enriched to the maximum extent through a modern extraction technology, the curative effect of the original formula is ensured to be retained to the maximum extent, and through a folic acid receptor, CD44 receptor and pH sensitive triple targeting mechanism, the medicine is enriched in cervical cancer tissues, the local medicine concentration is improved, the system toxicity is reduced, and accurate targeting delivery is realized.

The invention discloses preparation and application of short-chain polypeptide targeting breast cancer cells, and belongs to the technical field of biomedicine. The sequence of the main functional peptide chain is Thr-Gly-Ser-Val-Tyr-Phe-Lys (TGSVYFK), and the peptide sequence with the function comprises all peptide sequences which take the seven peptide sequences as a skeleton and add other amino acids and / or short peptide sequences at the front end and / or the rear end of the peptide chain. The invention can realize accurate targeting of in vivo / in vitro breast cancer cells, and has the characteristics of low biotoxicity, no hemolytic toxicity and the like. An anti-tumor preparation is prepared by coupling a carrier and loading a drug or directly coupling an anti-tumor drug, so that the off-target problem of the drug in the treatment process can be effectively solved, the killing effect on solid tumors is improved, side effects and systemic toxicity are reduced, and treatment on breast cancer is realized.

The invention relates to a composition for tumor local injection, a medical and mechanical combined product and application of the composition in preparation of a medicine for tumor local injection administration. The composition comprises an antitumor drug component, an immunologic adjuvant and a drug carrier. By means of the jet flow microneedle delivery device which is specially designed, tumor local drug delivery of anti-tumor drugs can be achieved, and the problem that the maximum drug dosage and the treatment effect are limited due to system toxicity in traditional intravenous drug delivery is solved. The high-concentration local administration of the composition provided by the invention not only improves the local treatment effect of tumors, but also can effectively generate tumor antigens. The tumor antigen generated in situ can be matched with an immunologic adjuvant in the composition to generate tumor specific immune cells on the premise that the immune system of a patient is not damaged due to the toxicity of a drug system, so that the immune response of the local part and the whole body of the patient to tumors is improved. Besides, in the subsequent treatment course after the initial treatment, only the composition of the immunologic adjuvant and the tumor specific polypeptide or the immunologic adjuvant can be given to maintain and enhance the established tumor specific immune response, and accumulated toxicity caused by repeated use of chemotherapeutic drugs is avoided.

The application discloses a preparation method and application of an anti-adhesion nano composite drug delivery system, relates to the technical field of adhesives, and discloses the following technical scheme: polyacrylamide and aldehyde functionalized starch with a preset mass ratio are taken, different amounts of zeolite imidazolate framework materials are added after mixing, and then the mixture after mixing is ground and sieved to obtain the anti-adhesion nano composite drug delivery system. The application can be used as a peritoneal tumor local drug delivery system, has high drug encapsulation efficiency and drug loading rate, can release antitumor drugs in tumor tissues specifically, continuously and stably through a tumor acid microenvironment, prolongs the exposure time of the drugs, improves the curative effect of the drugs, reduces the side effects of chemotherapy, can reshape an immune microenvironment, has a good killing effect on tumor cells, and has no systemic toxicity; meanwhile, the gel powder forms a physical barrier on a surgical wound after being changed into a gel by water, so that abdominal cavity adhesion caused by surgical trauma and chemotherapy can be reduced.

The application discloses a stable liver cancer embolism emulsion of raltitrexed drug gel and a preparation method and application thereof, and belongs to the field of pharmaceutical preparations. The emulsion is composed of iodized oil embolism agent and raltitrexed drug gel; the raltitrexed drug gel is a nanofiber network hydrogel formed by self-assembly of raltitrexed molecules in an aqueous phase through ultrasonic treatment, and simultaneously serves as an active pharmaceutical ingredient and an emulsion stabilizer. The iodized oil and the raltitrexed drug gel are physically mixed and injected through a three-way valve to form a stable oil-in-water emulsion or a water-in-oil emulsion, and any additional chemical surfactant or cosolvent is not needed. The emulsion has excellent physical stability, and can effectively solve the problems of easy aggregation and sedimentation of a traditional iodized oil emulsion and increased systemic toxicity caused by drug burst release. The emulsion has good embolism effect and drug release behavior, can significantly inhibit tumor growth, and has a wide clinical transformation prospect.

Provided are drug-device combinations and methods used for direct delivery of therapeutic drugs to the pituitary gland, wherein the drug-device combination also acts as a barrier between a sella turcica (pituitary fossa) and a sphenoid sinus to effectively trap or confine the drug substance within the sella turcica to prevent its premature escape away into the CSF from the target pituitary; thereby reducing or eliminating systemic toxicity of the drug substance. The drug-device combination includes a cap, a stem, a drug that is therapeutically effective for a pituitary gland disorder.

The application discloses an HGF mRNA lipid nanoparticle (LNP) and application thereof. The application constructs an HGF mRNA delivery system based on a lipid nanoparticle (LNP) and capable of targeting a liver, realizes controllable expression of HGF at an autoimmune lesion site, thereby inhibiting abnormal inflammation and immune response, promoting tissue repair, and simultaneously minimizing systemic toxicity and long-term safety risks.